ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 298 entries already.
Spanish VC firm Ysios Capital has unveiled InceptionBio, a €100 million fund dedicated to boosting Spanish biotech innovation. The initiative targets company creation from top-tier research, backed by public-private partnerships.
Finnish clinical stage biotech TenBoron Oy has landed a €7.6m grant from the European Union’s Horizon Europe Health 2025 programme. The funding will propel its boron carrier platform for a novel targeted radiotherapy into larger clinical trials for cancers with few remaining treatment options.
Immutrin, a UK biotech, has raised £65m (€75m) in Series A funding for a pioneering antibody designed to remove pre-existing amyloid deposits in amyloidosis.
Sanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated autoimmune diseases.
Membrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s bispecific antibody platform for hard-to-treat targets.
Featuring 100 exhibitors, keynote and podium speakers, behind-the-scenes access to a leading biotech campus, and a rich networking program, SLAS Europe 2026 is designed for professionals at every stage of their careers.
Biotech is entering its automated era. Robots run assays, AI designs molecules, and data drives decisions. For young scientists, the question is not survival, it is leadership. Will you adapt to the new lab, or help define it?
Austria’s biotech sector is gaining momentum as the EU Biotech Act opens new opportunities. BIOTECH AUSTRIA and EuropaBio join forces to strengthen innovation, competitiveness, and Europe’s role as a global biotech leader.
Discover ELRIG’s quarter two events – three focused scientific meetings showcasing the newest technologies, models, and strategies redefining drug discovery. Join global experts advancing complex cellular systems, automation, and innovative target screening.
Ipsen has announced the immediate withdrawal of its cancer drug Tazverik across all indications after serious safety issues emerged in an ongoing Phase III trial.